ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Postprandial Incretin Response in Women With Gestational Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01274052
Recruitment Status : Completed
First Posted : January 11, 2011
Last Update Posted : January 11, 2011
Sponsor:
Collaborators:
The Danish Diabetes Association
Aase and Ejnar Danielsens Foundation
The Novo Nordic Foundation
Information provided by:
University Hospital, Gentofte, Copenhagen

Brief Summary:

The researchers investigated nineteen pregnant women in third trimester and again postpartum. At the experimental days we performed a mealtest and drew blood for analyses of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), insulin, C-peptide and glucagon.

The researchers aimed to investigate whether women with gestational diabetes mellitus exhibit decreased postprandial GLP-1 responses, and if so, whether this deficiency ceases following delivery when normal glucose tolerance is reestablished.


Condition or disease Intervention/treatment
Gestational Diabetes Mellitus Other: Meal test

Detailed Description:

The researchers investigated nineteen pregnant women in third trimester and again postpartum. At the experimental days we performed a mealtest and drew blood for analyses of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), insulin, C-peptide and glucagon.

The researchers aimed to investigate whether women with gestational diabetes mellitus exhibit decreased postprandial GLP-1 responses, and if so, whether this deficiency ceases following delivery when normal glucose tolerance is reestablished.


Study Type : Observational
Actual Enrollment : 19 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Reduced Postprandial GLP-1 Response in Gestational Diabetes Mellitus: a Fully Reversible Phenomenon
Study Start Date : March 2007
Actual Primary Completion Date : July 2008
Actual Study Completion Date : July 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Group/Cohort Intervention/treatment
Gestational Diabetes Mellitus
Women with Gestational Diabetes Mellitus
Other: Meal test
Liquid meal test
Normal Glucose Tolerance
Women with Normal Glucose Tolerance
Other: Meal test
Liquid meal test



Biospecimen Retention:   Samples Without DNA
Blood Plasma


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Healthy pregnant woman were examined with a 75 g oral glucose tolerance test. Subjects with plasma glucose (PG) values at 120 min >9.0 mmol/l were diagnosed with gestational diabetes and subjects with PG <9.0 mmol/l were enrolled as healthy controls.
Criteria

Inclusion Criteria:

  • Normal haemoblobin
  • Willingness to participate

Exclusion Criteria:

  • First degree relative with diabetes
  • Diabetes before pregnancy
  • Positive islet cell- and GAD-65 autoantibodies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01274052


Locations
Denmark
Department of Internal Medicine, Glostrup Hospital
Glostrup, Denmark, 2600
Sponsors and Collaborators
University Hospital, Gentofte, Copenhagen
The Danish Diabetes Association
Aase and Ejnar Danielsens Foundation
The Novo Nordic Foundation
Investigators
Principal Investigator: Filip K Knop, MD PhD Diabetes Research Division, Gentofte Hopsital

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Filip K. Knop, MD PhD, Department of Internal Medicine F, University Hospital, Gentofte, Copenhagen
ClinicalTrials.gov Identifier: NCT01274052     History of Changes
Other Study ID Numbers: KA-060015
First Posted: January 11, 2011    Key Record Dates
Last Update Posted: January 11, 2011
Last Verified: January 2011

Keywords provided by University Hospital, Gentofte, Copenhagen:
Gestational diabetes mellitus
Meal test
Incretin hormones
Glucagon-like peptide-1 (GLP-1)
Glucose-dependent insulinotropic polypeptide
Insulin
C-peptide
Glucagon

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes, Gestational
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Pregnancy Complications
Glucagon
Gastric Inhibitory Polypeptide
Incretins
Gastrointestinal Agents
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs